Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024141 (
systemic lupus erythematosus
)
44,322
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Aim of the study was to compare the expression of monocytes C1qRp (
CD93
) in patients with
systemic lupus erythematosus
(
SLE
) with that of healthy controls and to determine the influence of glucocorticoids and LPS on C1qRp expression. Thirty-six
SLE
patients and 20 healthy controls were analyzed by flow cytometry. Additionally, monocytes from five patients and five controls were cultured and stimulated with dexamethasone, interferon-gamma and LPS, respectively, before the measurement of C1qRp expression. There was no difference in C1qRp expression between
SLE
and HC.
SLE
patients with no or only low dose steroids had a significantly higher C1qRp expression than those with higher doses. However, in vitro dexamethasone did not stimulate or down-regulate C1qRp expression. Upon LPS stimulation, C1qRp was significantly up regulated on monocytes both from patients and from controls. In conclusion, C1qRp expression and regulation was not altered in
SLE
patients. Possible relations with disease activity and medication need further investigations.
...
PMID:C1qRP (CD93) expression on peripheral blood monocytes in patients with systemic lupus erythematosus. 1667 32
In the present study, we characterize a polymorphism in the CD93 molecule, originally identified as the receptor for the C1q complement component (i.e., C1qRp, or AA4.1) in non-obese diabetic (NOD) mice. This allele carries a coding polymorphism in the first epidermal growth factor-like domain of
CD93
, which results in an amino acid substitution from Asn-->His at position 264. This polymorphism does not appear to influence protein translation or ecto-domain cleavage, as
CD93
is detectable in bone-marrow-derived macrophage and B-cell precursor lysates and in soluble form in the serum. The NOD
CD93
isoform causes a phenotypic aberrancy in the early B-cell developmental stages (i.e., pro-, pre-, immature, and transitional), likely related to a conformational variation. Interestingly, the NZB/W F1 strain, which serves as a murine model of
Lupus
, also expresses an identical
CD93
sequence polymorphism. Cd93 is located within the NOD Idd13 locus and is also tightly linked to the NZB/W F1 Wbw1 and Nkt2 disease susceptibility loci, which are thought to regulate natural killer T (NKT) cell homeostasis. Consistent with this genetic linkage, we found B6
CD93
(-/-) and B6.NOD(Idd13) mice to be susceptible to a profound CD4(+) NKT cell deficient state. These data suggest that Cd93 may be an autoimmune susceptibility gene residing within the Idd13 locus, which plays a role in regulating absolute numbers of CD4(+) NKT cells.
...
PMID:A novel CD93 polymorphism in non-obese diabetic (NOD) and NZB/W F1 mice is linked to a CD4+ iNKT cell deficient state. 2038 63